Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ticagrelor in Patients with Stable Coronary Disease and Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John J V McMurray
  • Scott D Solomon
  • Silvio E Inzucchi
  • Lars Køber
  • Mikhail N Kosiborod
  • Felipe A Martinez
  • Piotr Ponikowski
  • Marc S Sabatine
  • Inder S Anand
  • Jan Bělohlávek
  • Michael Böhm
  • Chern-En Chiang
  • Vijay K Chopra
  • Rudolf A de Boer
  • Akshay S Desai
  • Mirta Diez
  • Jaroslaw Drozdz
  • Andrej Dukát
  • Junbo Ge
  • Jonathan G Howlett
  • Tzvetana Katova
  • Masafumi Kitakaze
  • Charlotta E A Ljungman
  • Béla Merkely
  • Jose C Nicolau
  • Eileen O'Meara
  • Mark C Petrie
  • Pham N Vinh
  • Morten Schou
  • Sergey Tereshchenko
  • Subodh Verma
  • Claes Held
  • David L DeMets
  • Kieran F Docherty
  • Pardeep S Jhund
  • Olof Bengtsson
  • Mikaela Sjöstrand
  • Anna-Maria Langkilde
  • DAPA-HF Trial Committees and Investigators
View graph of relations

BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.

RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups.

CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).

Original languageEnglish
JournalThe New England journal of medicine
Volume381
Issue number21
Pages (from-to)1995-2008
ISSN0028-4793
DOIs
Publication statusPublished - 21 Nov 2019

    Research areas

  • Aged, Benzhydryl Compounds/adverse effects, Cardiovascular Agents/therapeutic use, Cardiovascular Diseases/mortality, Combined Modality Therapy, Diabetes Mellitus, Type 2/blood, Drug Therapy, Combination, Female, Glucosides/adverse effects, Glycated Hemoglobin A/analysis, Heart Failure/complications, Hospitalization, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Stroke Volume/drug effects, Ventricular Dysfunction, Left/complications

ID: 58252985